Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Cystine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.48 |
| ▸ | GRIN2D known ✓ | O15399 | 1/20 | 0.44 |
| ▸ | GRIN3B known ✓ | O60391 | 1/20 | 0.44 |
| ▸ | GRIN1 known ✓ | Q05586 | 1/20 | 0.44 |
| ▸ | GRIN2A known ✓ | Q12879 | 1/20 | 0.44 |
| ▸ | GRIN2B known ✓ | Q13224 | 1/20 | 0.44 |
| ▸ | GRIN2C known ✓ | Q14957 | 1/20 | 0.44 |
| ▸ | GRIN3A known ✓ | Q8TCU5 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | ARG1 | P05089 | 1/20 | 0.48 |
| ▸ | ARG2 | P78540 | 1/20 | 0.48 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.48 |
| ▸ | NOS2 | P35228 | 3/20 | 0.47 |
| ▸ | NOS1 | P29475 | 2/20 | 0.47 |
| ▸ | NOS3 | P29474 | 1/20 | 0.47 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.46 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.46 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.46 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cystine SCHEMBL258646 | 1.00 | ALOX15 (0.48) | ALOX15ALDH1A1ARG1ARG2PTGS1 | |
| Cystine SCHEMBL8158993 | 1.00 | ALOX15 (0.48) | ALOX15ALDH1A1ARG1ARG2PTGS1 | |
| Cystine SCHEMBL375413 | 1.00 | ALOX15 (0.48) | ALOX15ALDH1A1ARG1ARG2PTGS1 | |
| Cystine SCHEMBL258647 | 1.00 | ALOX15 (0.48) | ALOX15ALDH1A1ARG1ARG2PTGS1 | |
| Cystine SCHEMBL375414 | 1.00 | ALOX15 (0.48) | ALOX15ALDH1A1ARG1ARG2PTGS1 | |
| Cystine SCHEMBL375415 | 1.00 | ALOX15 (0.48) | ALOX15ALDH1A1ARG1ARG2PTGS1 | |
| Cystine SCHEMBL8158997 | 1.00 | ALOX15 (0.48) | ALOX15ALDH1A1ARG1ARG2PTGS1 | |
| Cystine SCHEMBL1818813 | 0.97 | ALOX15 (0.47) | ALOX15ALDH1A1ARG1ARG2PTGS1 | |
| Cystine SCHEMBL8087124 | 0.97 | ALOX15 (0.47) | ALOX15ALDH1A1ARG1ARG2PTGS1 | |
| Cystine SCHEMBL21409473 | 0.97 | ALOX15 (0.47) | ALOX15ALDH1A1ARG1ARG2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 417 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250032520-A1 | ORAL CANNABINOID COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISEASES AND DISORDERS | Avicanna Inc. (CA) | 2025-01-30 | — | — | US | claimed |
| CN-119120381-A | Method for rapidly generating CAR-T cells by using mesenchymal stem cell-derived engineering exosome-mediated mRNA | 博雅干细胞科技有限公司 | 2024-12-13 | — | — | CN | claimed |
| CN-119020257-A | Perfusion culture medium for mammalian CHO cells and application thereof | 信达生物制药(苏州)有限公司 | 2024-11-26 | — | — | CN | claimed |
| CN-118240740-B | Single-component CHO perfusion culture medium and application thereof | 上海迈邦生物科技有限公司 | 2024-09-03 | — | — | CN | claimed |
| CN-118496308-A | Design and application of self-response polypeptide molecular probe for optimizing coumarin two-photon fluorescence property | 南方医科大学南方医院 | 2024-08-16 | — | — | CN | claimed |
| CN-118480508-A | Culture medium capable of increasing expression of CD11b by THP-1 cells | 上海源培生物科技股份有限公司 | 2024-08-13 | — | — | CN | claimed |
| CN-118436807-A | Application of double (poly) tail lipid system based on all-trans retinoic acid and gene co-carrier system | 四川大学 | 2024-08-06 | — | — | CN | claimed |
| CN-118240740-A | High-performance single-component CHO perfusion culture medium and application thereof | 上海迈邦生物科技有限公司 | 2024-06-25 | — | — | CN | claimed |
| CN-115369069-B | 293 cell feed supplement culture medium and preparation and application thereof | 上海健士拜生物科技有限公司 | 2023-12-19 | — | — | CN | claimed |
| CN-117165511-A | Neutral feed supplement culture medium for cell culture and preparation method and application thereof | 上海迈邦生物科技有限公司 | 2023-12-05 | — | — | CN | claimed |
| CN-103937741-A | Preparation method of enhanced CIK (Cytokine Induced Killer) cell, and cell preparation | ANDERSON CELL BIOLOGY HUBEI CO LTD | 2014-07-23 | — | — | CN | claimed |
| CN-103857789-A | Method for preparing a basic culture medium for mesenchymal stem cells, basic culture medium for mesenchymal stem cells, and cell therapeutic agent cultured and differentiated using same | SEWON CELLONTECH CO LTD | 2014-06-11 | — | — | CN | claimed |
| EP-2059518-B1 | SALTS OF BENZIMIDAZOLYL PYRIDYL ETHERS AND FORMULATIONS THEREOF | NOVARTIS AG (CH) | 2011-04-06 | — | — | EP | claimed |
| US-20100168060-A1 | SALTS OF BENZIMIDAZOLYL PYRIDYL ETHERS AND FORMULATIONS THEREOF | NOVARTIS AG (CH) | 2010-07-01 | — | — | US | claimed |
| EP-2059518-A2 | SALTS OF BENZIMIDAZOLYL PYRIDYL ETHERS AND FORMULATIONS THEREOF | Novartis AG (CH) | 2009-05-20 | — | — | EP | claimed |
| WO-2008027523-A2 | SALTS OF BENZIMIDAZOLYL PYRIDYL ETHERS AND FORMULATIONS THEREOF | NOVARTIS AG (CH) | 2008-03-06 | — | — | WO | claimed |
| EP-0711154-B1 | STABILIZED PHARMACEUTICAL COMPOSITION CONTAINING BUPROPION | WELLCOME FOUND (GB) | 2003-02-12 | — | — | EP | claimed |
| US-5731000-A | Stabilized pharmaceutical composition containing bupropion | GLAXO WELLCOME INC. (US) | 1998-03-24 | — | — | US | claimed |
| EP-0711154-A1 | STABILIZED PHARMACEUTICAL COMPOSITION CONTAINING BUPROPION | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-05-15 | — | — | EP | claimed |
| WO-1995003791-A1 | STABILIZED PHARMACEUTICAL COMPOSITION CONTAINING BUPROPION | THE WELLCOME FOUNDATION LIMITED (GB) | 1995-02-09 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168060-A1 | SALTS OF BENZIMIDAZOLYL PYRIDYL ETHERS AND FORMULATIONS THEREOF | PIR, BRD8, PHOSPHO1 | PTGS1 3550/4885GRIN2D 1703/4885GRIN3B 2353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.